Developing Self-Management Interventions After HCT
8. september 2021 oppdatert av: University of Florida
Developing the Bio-behavioral Foundation for Self-Management of Psycho-neurological Symptoms in Hematopoietic Cell Transplant (HCT) Survivors
This is a prospective, longitudinal, observational trial to evaluate quality of life in hematopoietic stem cell transplant survivors.
Studieoversikt
Status
Fullført
Intervensjon / Behandling
Detaljert beskrivelse
Hematopoietic stem cell transplant (HSCT) survival rates continue to increase as treatment protocols improve.
However, HSCT survivors face many mental, emotional, and physical challenges that threaten quality of life (QOL), which, according to the American Society of Clinical Oncology, is the most important treatment outcome next to survival.
Psychoneurologic symptoms (PNS) significantly diminish QOL after HSCT.
PNS often co-occur and may be associated with inflammation related to perturbations of the gut microbiota.
This project will track the interplay among these factors in 50 adult survivors of HSCT to lay the groundwork for a targeted dietary self-management intervention to mitigate PN symptoms.This is to be achieved by elucidating the complex bio-behavioral mechanisms of distressing symptoms in HCT patients such as neurocognitive dysfunction, fatigue, anxiety, depression and pain, inflammation (cytokines and C-reactive protein), gut microbiota [(GM) richness and diversity] and diet (macronutrients: carbohydrates, fats and proteins).
Studietype
Observasjonsmessig
Registrering (Faktiske)
49
Kontakter og plasseringer
Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.
Studiesteder
-
-
Florida
-
Gainesville, Florida, Forente stater, 32608
- UF Health Cancer Hospital
-
-
Deltakelseskriterier
Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
18 år til 99 år (Voksen, Eldre voksen)
Tar imot friske frivillige
Nei
Kjønn som er kvalifisert for studier
Alle
Prøvetakingsmetode
Sannsynlighetsprøve
Studiepopulasjon
Hematopoietic Stem Cell Transplant (HSCT) Survivors.
Survival rates continue to increase as treatment protocols improve; by 2030, an estimated half-million HSCT recipients in the United States will be long-term survivors.
However, HSCT survivors continue to face many mental, emotional, and physical challenges that threaten QOL, which, according to the American Society of Clinical Oncology, is the most important treatment outcome next to survival.
Therefore, a prospective, observational design to longitudinally examine these factors in 50 adult (at least 18 years of age) survivors of HSCT to lay the groundwork for the future development of a targeted dietary self-management intervention to mitigate PN symptoms in this growing group of HSCT survivors is being planned.
Beskrivelse
Inclusion Criteria:
- patients scheduled for HSCT with the Bone Marrow Transplant Program at the UF Health Cancer Center (UFHCC) [specifically bone marrow diseases, myelodysplastic-myeloproliferative diseases, lymphoma, bone marrow neoplasm or leukemia]
- Written informed consent obtained from the subject to take Mini-Mental State Examination (MMSE) prior to enrollment on the study and to comply with all the study-related procedures.
- Score at least a 24 on the Mini-Mental State Examination (MMSE) prior to enrollment
Exclusion Criteria:
- Subjects with any of the following will not be eligible for study participation:
- Patient has prior history of HSCT
- Patient has diagnosis that could interfere with neurocognitive function such as dementia, a concurrent diagnosis of systemic lupus erythematous or multiple sclerosis, diagnosis of a major depressive disorder, schizophrenia or untreated bipolar disease.
- Pregnant women are not eligible for transplant therefore will not be enrolled on the study
- Inability to comply with the study and/or follow-up procedures.
Studieplan
Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.
Hvordan er studiet utformet?
Designdetaljer
Kohorter og intervensjoner
Gruppe / Kohort |
Intervensjon / Behandling |
|---|---|
|
HSCT Survivors
PNS tracking will occur through blood and stool samples to track the interplay among psychoneurologic symptoms (PNS) as they relate to diminished QOL among survivors of HSCT.
|
Through blood and stool samples the study team will track the interplay among PNS as they relate to diminished QOL.
Symptoms tracked include neurocognitive dysfunction, fatigue, anxiety, depression and pain, inflammation (cytokines and C-reactive protein), gut microbiota [(GM) richness and diversity] and diet (macronutrients: carbohydrates, fats and proteins).
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Change in plasma levels of inflammatory markers (cytokines and CRP) of individuals post allogeneic HSCT
Tidsramme: Baseline; Day 30; Day 100
|
Cytokines will be analyzed using a multiplex assay by Millipore Company.
Compared to the traditional enzyme-linked immunosorbant assays (ELISA), the multiplex is comparable and more sensitive to lower concentration levels of cytokines than the ELISA.
One laser identifies a specific bead and another laser identifies the reported antibody associated with the bead-bound cytokine.
One hundred beads for each of the 17 cytokines in every sample are assayed and a mean cytokine binding for the sample is determined.
The manufacturer reports that the assay accurately measures cytokine values in a range of 1-2500pg/ml.
Serum CRP will be measured using the ALPCO's (American Laboratory Products Company) high-sensitivity CRP assay which uses latex particle enhanced immunoturbidimetry for quantitative CRP determination.
|
Baseline; Day 30; Day 100
|
|
Change in diversity and levels of fecal microbes of individuals post allogeneic HSCT
Tidsramme: Baseline; Day 30; Day 100
|
Fecal microbial DNA will be extracted from between 50-200 mg of fecal material.
The 16S ribosomal gene (V4 region) of each sample will be amplified using a barcoding system to allow multiplexing with the Illumina MiSeq system.
We will use UNIFRAC algorithm to evaluate the null hypothesis that the structure of the microbial community is insensitive to cGVHD and symptoms of cGVHD.
Differences in taxa are implicated by our high throughput sequencing methods will be confirmed by other techniques including culturing (where appropriate) and qPCR with taxa-specific primers.
|
Baseline; Day 30; Day 100
|
|
Change in behavioral responses (symptoms) of individuals post allogeneic HSCT
Tidsramme: Baseline; Day 30; Day 100
|
Baseline; Day 30; Day 100
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Health Promoting Lifestyle Profile II (HPLPII)
Tidsramme: Baseline; Day 30; Day 100
|
The Health Promoting Lifestyle Profile II (HPLPII) will be used to identify lifestyle choices that may affect relationships and differences between groups.
HPLPII measures health promoting behaviors across several dimensions with subscales of health responsibility, physical activity, nutrition, spiritual growth, interpersonal relations and stress management.
This is a 52-item summated behavior rating scale using a 4-point response format to measure the frequency of self-reported health-promoting behaviors.
It is a well validated toll and takes approximately 10 minutes to complete.
|
Baseline; Day 30; Day 100
|
|
Brief Pain Inventory (BPI)
Tidsramme: Baseline; Day 30; Day 100
|
Pain will be assessed using the Brief Pain Inventory (BPI).
The BPI was created to evaluate two dimensions of pain: 1) the severity and 2) the interference.
This tool is well validated with Cronbach's alpha .80-.87 pain severity and .89-.92 for interference.22
The BPI consists of a body diagram to indicate location of pain and a general question asking if pain is present.
Four items assess pain intensity or severity and seven item s assess pain interference.
Both use an eleven point scale ranging from 0 (no pain or interference) to 10 (worst pain or interference).
This instrument takes approximate five minutes to complete.
|
Baseline; Day 30; Day 100
|
|
Hospital Anxiety and Depression Scale (HADS)
Tidsramme: Baseline; Day 30; Day 100
|
Depressive symptoms will be assessed using the subscale for depression from the Hospital Anxiety and Depression Scale (HADS).
23This instrument is used to assess the presence and severity of anxiety and depressive symptoms over a seven day period.
The depression subscale is comprised of seven items using a four point scale ranging from 0 (least severe) to 3 (most severe).
Cronbach's alpha has been found to be high (.82-.90) for the HADS depression subscale.
|
Baseline; Day 30; Day 100
|
|
Brief Fatigue Inventory (BFI)
Tidsramme: Baseline; Day 30; Day 100
|
Fatigue will be assessed using the Brief Fatigue Inventory (BFI).
The BFI is a nine item, eleven point scale that assesses physical, affective, cognitive and social domains in a two dimensions, fatigue intensity and interference.
Severity scores are as follows: 1) mild (1-3), 2) moderate (4-6) and 3) severe (7-10).
This tool is well establish and validated.
The Cronbach's alpha ranged from .95-.96 for individual items and an internal consistency of .96
overall.
The questionnaire takes approximately five minutes to complete and a global score can be ascertained by averaging the total score.
|
Baseline; Day 30; Day 100
|
|
Memorial Symptom Assessment Scale (MSAS-SF)
Tidsramme: Baseline; Day 30; Day 100
|
To comprehensively explore symptoms, the Memorial Symptom Assessment Scale (MSAS-SF) will be used to measure multiple dimensions (frequency, severity, and distress) of 32 common cancer symptoms.
The Cronbach alpha for the MSAS-SF subscales ranged from .76-.86 and the test-retest correlation coefficients ranged from .86-.94 at one day and one week respectively.
The total time to complete this form is approximately 10 minutes.
This form allows for patients to identify and quantify "other" symptoms.
|
Baseline; Day 30; Day 100
|
|
Functional Assessment of Cancer Therapy-Bone Marrow Transplantation (FACT-BMT)
Tidsramme: Baseline; Day 30; Day 100
|
Health related quality of life (HRQOL) will be measured using the Functional Assessment of Cancer Therapy- Bone Marrow Transplantation (FACT-BMT).
This is a well validated HRQOL measure.
This is a 27-item questionnaire asking questions across four domains: physical well-being, social well-being, emotional well-being and functional well-being.
This measure takes about 10 minutes to complete.
|
Baseline; Day 30; Day 100
|
Samarbeidspartnere og etterforskere
Det er her du vil finne personer og organisasjoner som er involvert i denne studien.
Sponsor
Samarbeidspartnere
Etterforskere
- Hovedetterforsker: Debra L Kelly, PhD, RN, OCN, College of Nursing, University of Florida
Publikasjoner og nyttige lenker
Den som er ansvarlig for å legge inn informasjon om studien leverer frivillig disse publikasjonene. Disse kan handle om alt relatert til studiet.
Studierekorddatoer
Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.
Studer hoveddatoer
Studiestart (Faktiske)
4. februar 2019
Primær fullføring (Faktiske)
31. juli 2021
Studiet fullført (Faktiske)
31. juli 2021
Datoer for studieregistrering
Først innsendt
26. september 2018
Først innsendt som oppfylte QC-kriteriene
16. oktober 2018
Først lagt ut (Faktiske)
17. oktober 2018
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
9. september 2021
Siste oppdatering sendt inn som oppfylte QC-kriteriene
8. september 2021
Sist bekreftet
1. september 2021
Mer informasjon
Begreper knyttet til denne studien
Nøkkelord
Andre studie-ID-numre
- IRB201802329
- R21NR017749 (U.S. NIH-stipend/kontrakt)
- OCR18772 (Annen identifikator: University of Florida)
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
UBESLUTTE
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Nei
Studerer et amerikansk FDA-regulert enhetsprodukt
Nei
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .